Aurinia Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Aurinia Pharmaceuticals

04/05/2023 14:32

* Aurinia Pharmaceuticals Inc  AUPH.OQ  reported a quarterly
adjusted loss of 18 cents​​ per share for the quarter ended in
March. The mean expectation of seven analysts for the quarter
was for a loss of 22 cents per share.
    * Revenue rose 59.1% to $34.41 million from a year ago;
analysts
expected $27.87 million. 
    * Aurinia Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 18 cents​.
    * The mean earnings estimate of analysts had risen by
about 17% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Aurinia Pharmaceuticals Inc shares had risen by 6.7% this
quarter and gained 170.6% so far this year.
    * The company reported a quarterly loss of $26.21 million.
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.22          -0.18          Beat
 Dec. 31 2022      -0.27          -0.18          Beat
 Sep. 30 2022      -0.17          -0.06          Beat
 Jun. 30 2022      -0.22          -0.25          Missed